Reviva Pharmaceuticals Holdings, Inc. (RVPH)
0.3676
+0.03
(+8.12%)
USD |
OTCM |
Nov 06, 16:00
Reviva Pharmaceuticals Holdings Enterprise Value : -14.93M for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | -14.93M |
| November 05, 2026 | -15.29M |
| November 04, 2026 | -14.76M |
| November 03, 2026 | -14.49M |
| November 02, 2026 | -14.12M |
| October 30, 2026 | -15.16M |
| October 29, 2026 | -14.61M |
| October 28, 2026 | -14.31M |
| October 27, 2026 | -13.85M |
| October 26, 2026 | -14.17M |
| October 23, 2026 | -13.87M |
| October 22, 2026 | -13.52M |
| October 21, 2026 | -13.92M |
| October 20, 2026 | -13.72M |
| October 19, 2026 | -13.85M |
| October 16, 2026 | -13.58M |
| October 15, 2026 | -13.52M |
| October 14, 2026 | -13.48M |
| October 13, 2026 | -13.25M |
| October 12, 2026 | -13.32M |
| October 09, 2026 | -13.19M |
| October 08, 2026 | -13.26M |
| October 07, 2026 | -13.19M |
| October 06, 2026 | -13.05M |
| October 05, 2026 | -13.06M |
| Date | Value |
|---|---|
| October 02, 2026 | -13.19M |
| October 01, 2026 | -13.19M |
| September 30, 2026 | -13.58M |
| September 29, 2026 | -13.49M |
| September 28, 2026 | -13.48M |
| September 25, 2026 | -13.45M |
| September 24, 2026 | -12.93M |
| September 23, 2026 | -13.45M |
| September 22, 2026 | -12.82M |
| September 21, 2026 | -13.19M |
| September 18, 2026 | -13.45M |
| September 17, 2026 | -13.16M |
| September 16, 2026 | -13.32M |
| September 15, 2026 | -13.45M |
| September 14, 2026 | -13.45M |
| September 11, 2026 | -12.73M |
| September 10, 2026 | -13.19M |
| September 09, 2026 | -12.77M |
| September 08, 2026 | -12.69M |
| September 04, 2026 | -12.80M |
| September 03, 2026 | -12.67M |
| September 02, 2026 | -12.73M |
| September 01, 2026 | -13.06M |
| August 31, 2026 | -13.45M |
| August 28, 2026 | -12.95M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.715B |
| Corcept Therapeutics, Inc. | 7.597B |
| Veru, Inc. | 13.04M |
| Johnson & Johnson | 692.32B |
| Eli Lilly & Co. | 1.319T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.448M |
| Total Expenses (Quarterly) | 2.448M |
| EPS Diluted (Quarterly) | -0.1853 |
| Earnings Yield | -630.4% |
| Normalized Earnings Yield | -630.41 |